Actelion Pharmaceuticals Ltd

act-293987 - selexipag

 

Study ID Status Type Title
AC-065A302 Completed Results Summary A multicenter, double-blind, placebo-controlled Phase 3 study assessing the safety and efficacy of selexipag on morbidity and mortality in patients With pulmonary arterial hypertension
AC-065A304 Completed Results Summary Multicenter, open-label, single-group study to assess the tolerability and the safety of the transition from inhaled treprostinil to oral selexipag in adult patients with pulmonary arterial hypertension
AC-065C202 Completed Results Summary A multi-center, double-blind, randomized, placebo-controlled, parallel group, exploratory Phase 2 study to assess efficacy and safety of selexipag in adult subjects with Raynaud’s Phenomenon secondary to Systemic Sclerosis
NS-304/-02 Completed Results Summary A multicentre, multinational, open-label, single-dose acute hemodynamic study followed by a multicentre, multinational, randomized, double-blind, parallel-group, placebo controlled study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy (proof-of-concept) of ACT-293987 (NS-304) in the treatment of pulmonary arterial hypertension in subjects aged 18 years and over